1. Левин Я.И., Артеменко А.Р. Фототерапия. М., 1996.
2. Левин Я.И., Ковров Г.В. Некоторые современные подходы к терапии инсомнии. Лечащий врач. 2003; 4: 18–32.
3. Akerstedt T, Gillberg M. Subjective and objective sleepiness in the active individual. Int Neurosci 1990; 52 (1–2): 29–37.
4. Ancoli-Israel S, Cole R, Alessi C et al. The role of actigraphy in the study of sleep and circadian rhythms. Sleep 2003; 26 (3): 342–92.
5. Boeve BF, Silber MH, Saper CB et al. Pathophysiology of REM sleep behavior disorder and relevance to neurodegenerative disease. Brain 2007; 130: 2770–88.
6. Braak H, Del Tredici K, Rub U et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 197–11.
7. Brzezinski A. Mechanisms of disease: melatonin in humans. New Engl J Med 1997; 336 (3): 186–95.
8. Brusco LI, Marquez M, Cardinali DP. Melatonin treatment stabilized chronobiologic and cognitive symptoms in Alzheimer’s disease. Neuroendocrinol Lett 2000; 21: 39–42.
9. Buysee DJ, Reynolds CF, Monk TH et al. The Pittsburg sleep quality index: a new instrument for psychiatric practice and reseach. Psychiatry Res 1989; 28 (2): 193–213.
10. Cardinali DP, Brusco LI, Liberczuk C, Furio AM. The use of melatonin in Alzheimer’s disease. Neuroendocrinol Lett 2002; 23 (Suppl. 1): 20–3.
11. Chaudhuri KR. Nocturnal symptom complex in Parkinson’s disease and its management. Neurology 2003; 61: S17–23.
12. Chaudhury KR, Pal S, DiMarco A et al. Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002; 73 (6):629–35.
13. Cohen-Mansfield J, Garfinkel D, Lipson S. Melatonin for treatment of sundowning in elderly patients with dementia – a preliminary study. Arch Gerontol Geriartr 2000; 31: 65–76.
14. Comella CL. Sleep disorders and excessive daytime sleepiness in Parkinson’s disease: an overview. J Neural Transm Suppl 2006; 349–55.
15. Delagrange P, Atkinson J, Boutin J A et al. Therapeutic perspectives for melatonin agonist and antagonists. J Neuroendocrinol 2003; 15 (4): 442–8.
16. Dowling GA, Mastick J, Aminoff MJ. Melatonin for sleep disturbances in Parkinson’s disease: a pilot study. Sleep Res Online 2003; 5: 99–103.
17. Dowling GA, Mastick J, Colling E et al. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med 2005; 6: 459–66.
18. Dubocovic ML. Melatonin receptors: are there multiple subtypes? Trends Pharmacol Sci 1995; 16: 50–6.
19. Ekmekcioglu C, Thalhammer T, Humpeler S et al. The melatonin receptor subtype MT2 is present in the human cardiovascular system. J Pineal Res 2003; 35 (1):40–4.
20. Fainstein I, Binetto A, Brusco LI et al. Effects of melatonin in elderly patients with sleep disturbances. Curr Ther Res 1997; 58: 990–1000.
21. Factor SA , McAlarney T, Sanches-Ramos JR et al. Sleep disorders and sleep effect in Parkinson’s disease. Mov Disord 1990; 5: 280–5.
22. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12 (3): 189–98.
23. Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignant – like syndrome due to levodopa therapy withdrawal. JAMA 1985; 2792–5.
24. Friedman JH, Chou KL. Sleep and fatigue in Parkinson's disease. Parkinsonism Relat Disord 2004; 10 (Suppl. 1): S27–35.
25. Frucht S, Rogers JD, Greene PE et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexol and ropinirole. Neurology 1999; 52: 1908–10.
26. Gagnon JF, Postuma RB, Mazza S et al. Rapid-eye-movement sleep behavior disorders and neurodegenerative disease. Lancet Neuro 2006; 5: 424032.
27. Gibb WR, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol 1989; 15: 27–44.
28. Hamilton M, White JM. Clinical syndromes in depressive states. J Men Sci 1959; 105: 985–98.
29. Hilten JJ, Weggeman M, Van der Velde EA et al. Sleep, excessive daytime sleepiness and fatigue in Parkinson’s disease 1993; 5: 235–44.
30. Hoddes E, Zarcone V, Smythe H et al. Quantification of sleepiness: a new approach. Psychophysiology 1973; 10 (4): 431–6.
31. Holliman BJ, Chyka PA. Problems in assessment of acute melatonin overdose. South Med J 1997; 90 (4):451–53.
32. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17 (5): 427–42.
33. Hughes AJ, Ben-Shlomo Y, Daniel SE et al. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 42: 1142–6.
34. Ianas O, Olinescu R, Badescu I. Melatonin involvement in oxidative processes. Endocrinologie 1991; 29 (3–4):147–153.
35. Jellinger KA. Pathology of Parkinson’s disease: changes other than the nigrostrial pathway. Mol Chem Neuropulhology 1991; 14: 153–97.
36. Johns MW. Daytime sleepiness, snoring and obstructive sleep apnea. The Epworth Sleepiness Scale. Chest 1993; 103: 30–6.
37. Johns MW. Sleepiness in different situations measured by the Epworth sleepiness scale. Sleep 1994; 17 (8): 703–10.
38. Karlsen KH, Larsen JP, Tandberg E et al. Influence of clinical and demographic variables on quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999; 6: 431–5.
39. Kaynak D, Kiziltan G, Kaynak H et al. Sleep and sleepiness in patients with Parkinson’s disease before and after dopaminergic treatment. Eur J Neirol 2005; 12: 199–207.
40. Klawans HL, Goets C, Bergen D. Levodopa-induced myoclonus. Arch Neural 1975; 32: 331–4.
41. Kelly DD. Disorders of sleep and consciousness. In Principles of Neuronal Science Norwalk: Appleton and Lange 1991; p. 805–19.
42. Lacy C, Armstrong LL, Ingrim N, Lance LL. Drug Information Handbook. Hudson: Lexi-Comp 1995.
43. Larsen JP, Tandberg E. Sleep disorders in patients with Parkinson’s disease: epidemiology and management. CNS Drugs 2001; 15 (4): 267–75.
44. Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson’s disease. Clin Neuropharmacol 1988; 11: 512–9.
45. Lee KA. Self-reported sleep disturbances in employed women. Sleep 1992; 15 (6): 493–8.
46. Levin II, Gavrilov DG, Goldstein IA et al. Music of the Brain – the new method of treatment of insomnia, anxiety, depression. Abstracts of the 2-nd Israel International Congress on Integrative Medicine «Acupuncture & Integrative Medicine Enter the 21-st Century» 1999; p. 24–5.
47. Lindvall O, Rehnrona S, Brundin B et al. Human fetal dopamine neurons grafted into the striatum in two patients in Parkinson’s disease. Arch Neurology 1989; 46: 615–31.
48. Marinus J, Visser M, van Hilten JJ et al. Assessment of sleep and sleepiness in Parkinson’s disease. Sleep 2003; 26 (8): 1049–54.
49. Mahlberg R, Kunz D, Sutej I, Hellweg R. Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer’s disease: an open-label pilot study using actigraphy. J Clin Psychopharmacol 2004; 24: 456–9.
50. Mishima K, Okawa M, Hozumi S, Hishikawa Y. Supplementary administration of bright light and melatonin as potent treatment for disorganized circadian rest-activity and dysfunctional autonomic and neuroendocrine system in institutionalized demented elderly persons. Chronobiol Int 2000; 17: 419–32.
51. Monderer R, Thorpy M. Sleep disorders and daytime sleepiness in Parkinson’s disease. Curr Neurol Neurosci Rep 2009; 9: 173–80.
52. Nowak JZ, Zawilska JB. Melatonin and its physiological and therapeutic properties. Pharm World Sci 1998; 20 (1): 18–20.
53. Olakowska E, Marcol W, Kotulska K et al. The role of melatonin in the neurodegenerative disease. Bratisl Lek Listy 2005; 106 (4–5): 171–4.
54. Olanow CW, Koller WC. An algorithm (decision free) for the managements of Parkinson’s disease: treatment guidelines. Neurology 2001; 50 (Suppl. 3): 1–63.
55. Pal PK, Calne S, Samii A et al. A review of normal sleep and its disturbances in Parkinson’s disease. Perkinsonism Related Disorders1999; 5: 1–17.
56. Pacchetti C, Manni R, Zangaglia R et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson’s disease. Mov Disord 2005; 20: 1439–48.
57. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995; 4: 241–8.
58. Ray DB, Bliwise DL. Movement disorders specific to sleep and nocturnal manifestation of waking movement disorders. Mov Dis NY: McGraw-Hill 1997; p. 678–714.
59. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12 (2): 151–80.
60. Reiter RJ, Robinson J. Melatonin. Bantam books 1995. New York.
61. Ruzsas C, Mess B. Melatonin and aging. A brief survey. Nueroendocrinol Lett 2000; 21: 17–23.
62. Sadeh A, Acebo C. The role of actigraphy in sleep medicine. Sleep Med Rev 2002; 6 (2): 113–24.
63. Scaglione C, Vignatelli L, Plazzi G et al. Rem sleep behavior disorder in Parkinson’s disease: a questionnaire-based study. Neurol Sci 2005; 25: 316–21.
64. Schulman LM, Taback RS, Bean J et al. Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov Dis 2001; 16 (3): 507–10.
65. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. Third symposium on Parkinson's disease. Gillingham FG, Donaldson MC (ed.) Edinburgh 1969; p. 152–7.
66. Singer C, Tractenberg RE, Kaye J et al. Alzheimer’s disease cooperative study: A Multycenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. Sleep 2003; 26: 893–901.
67. Stocchi F, Brusa L, Vacca L et al. Sleep disturbances in Parkinson’s disease. Eur J Neurol 2000; 7 (Suppl. 4): 21–5.
68. Suzuki K, Okuma Y, Hattori N et al. Characteristics of sleep disturbances in Japanese patients with Parkinson’s disease. A study using Parkinson’s disease sleep scale. Mov Disord 2007; 22: 1245–51.
69. Swaab DF, Fliers E, Partimann TS. The Suprachiasmatic nucleus of the human brain in regulation to sex, age, and senile dementia. Brain Res 1985; 342: 37–44.
70. Tan DX, Manchester LC, Hardeland R et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid and an antioxidant vitamin. J Pineal Res 2003; 34 (1): 75–8.
71. Van Someren EJW. Circadian and sleep disturbances in the elderly. Exp Gerontol 2000; 35: 1229–37.
72. Weintraub D, Moberg PJ, Duba JE et al. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J Am Geriatr Soc 2004; 52: 784–8.

Н.В.Федорова, А.В.Никитина, Е.В.Губанова 

Кафедра неврологии РМАПО; 
Центр экстрапирамидных заболеваний, Москва